Liver enzymes in high-risk patients diagnosed with COVID-19

Authors

Keywords:

liver enzymes, COVID-19, liver damage.

Abstract

Introduction: It is important to know the alterations in liver enzymes in patients with COVID-19, as markers of liver damage.
Objective: To identify alterations in liver enzymes in high-risk patients with COVID-19.
Methods: A prospective descriptive study was carried out on alterations in liver enzymes in 56 patients admitted with COVID-19. The variables studied were age, sex, evolution towards gravity, and liver enzymes. Serum samples were taken on the first day of admission and on the fifth day to determine liver enzymes. The Ritis index was also found.
Results: The average age was 66.64 ± 13.12 years, 51.8% were older men and 37.5% progressed towards severity. In all enzymes there was an increase in the mean on the fifth day of the study. Lactate dehydrogenase (LDH) and γ-glutamyl transpeptidase (GGT) were found to be high in most of the patients from the first day. On the fifth day, aspartate aminotransferase (AST) was high in 71.4% of non-severe patients and alanine aminotransferase (ALT) in severe cases. At the beginning, a Ritis index < 1 was more frequent, but on the fifth day the Ritis index > 1 increased by 42.9% in seriously ill. 56.6% of seriously ill patients modified this index on the fifth day.
Conclusions: The elevation of the mean liver enzymes on the fifth day was demonstrated. LDH and GGT remained high from the beginning of the disease. The majority of severe patients reversed the Ritis index on the fifth day.

Downloads

Download data is not yet available.

Author Biographies

Naivy Sánchez Vera, Hospital Miliar Manuel Fajardo Rivero

especialista de primer grado en Laboratorio Clínico y MGI

Danay Saavedra Hernández, Centro de Inmunología Molecular, La Habana.

especialista de 2do grado en inmunología

Carlos Jorge Hidalgo Mesa, Hospital Miliar Manuel Fajardo Rivero

especialista de segundo grado en medicina interna

Maykel Aguila López, Hospital Universitario “Arnaldo Milián Castro”. Villa Clara

especialista de primer grado en Cardiología y MGI

Yaneisy Negrín Medina, Hospital Miliar Manuel Fajardo Rivero

especialista de primer grado en Laboratorio Clínico

Iliana Rodríguez García, Hospital Miliar Manuel Fajardo Rivero

licenciada en Laboratorio Clínico

References

1. Serra Valdés MA. COVID-19. De la patogenia a la elevada mortalidad en el adulto mayor y con comorbilidades. Rev haban cienc méd. 2020 [acceso: 11/10/2021]; 19(3):e3379. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2020000300004&lng=es

2. Samada Suárez M. Daño hepático por la COVID-19. Boletín Científico del Cimeq. 2020 [acceso: 01/10/2021]; 1(11):7. Disponible en: https://instituciones.sld.cu/bolcimeq/2020/05/25/dano-hepatico-por-la-covid-19/

3. Téllez L, Martín Mateos RM. Actualización en COVID-19 y enfermedad hepática. Rev. Gastroenterol Hepatol. 2020 [acceso: 08/10/2021]; 43(8):472-80. Disponible en: https://doi.org/10.1016/j.gastrohep.2020.06.006

4. Padilla Machaca PM, Cárdenas Ramírez BE, Cabrera Cabrejos MC. Impacto del COVID-19 en las enfermedades hepáticas y la salud pública en el Perú. Rev. gastroenterol. 2020 [acceso: 11/10/2021]; 40(2):162-72. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1022-51292020000200162&lng=es

5. Velarde Ruiz Velasco JA, García Jiménez ES, Remes Troche JM. Manifestaciones hepáticas y repercusión en el paciente cirrótico de COVID-19. Rev. Gastroenterol. Méx. 2020 [acceso: 01/10/2021]; 85(3):303-11. Disponible en: http://www.revistagastroenterologiamexico.org/es-manifestaciones-hepaticas-repercusion-el-paciente-articulo-S0375090620300550

6. Mantovani A, Beatrice G, Dalberi A. Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis. Liver International. 2020 [access: 08/10/2021]; 40(6):1316-20. Disponible en: https://doi.org/10.1111/liv.14465

7. León Gómez J. Implicaciones hepáticas en la pandemia por COVID-19. Rev Col Gastroenterol. 2020 [acceso: 08/10/2021]; 35(1):30-6. Disponible en: https://doi.org/10.22516/25007440.535

8. MINSAP. Protocolo de actuación nacional para la COVID-19. Versión 1.6. La Habana; 2021. [acceso: 01/08/2022]. Disponible en: https://files.sld.cu/editorhome/files/2021/03/Protocolo-COVID19-Cuba_versi%C3%B3n-1.6.pdf

9. León Álvarez JL, Calderón Martínez M, Gutiérrez Rojas AR. Análisis de mortalidad y comorbilidad por Covid-19 en Cuba. Rev cubana med. 2021 [acceso: 11/10/2021]; 60(2):e2117. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232021000200004&lng=es

10. Sun J, Aghemo A, Forner A, Luca Valenti L. COVID-19 and liver disease. Liver International. 2020 [access: 08/10/2021]; 40(6):1278-81. Disponible en: https://doi.org/10.1111/liv.14470

11. Aguilar Gamboa FR, Vega Fernández JA, Suclupe Campos DO. SARS-CoV-2: mucho más que un virus respiratorio. Arch méd Camagüey. 2021 [acceso: 11/10/2021]; 25(2):e801. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-02552021000200014&lng=es

12. Almeida Costa T, Cunha Lima MA, Kniess I, Marques Vieira L, Delmondes Freitas Trindade LM. Cambios en la función hepática causados por COVID-19 y su impacto en el resultado clínico del paciente: una revisión sistemática. Rev. Colomb. Gastroenterol. 2021 [acceso: 11/10/2021]; 36(3):302-12. Disponible en: https://revistagastrocol.com/index.php/rcg/article/view/713/1208

13. Kumar MP, Mishra S, Jha DK, Shukla J, Choudhury A, Mohindra R, et al. Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis. Hepatol Int. 2020 [access: 08/10/2021]; 14:711–22. Disponible en: https://doi.org/10.1007/s12072-020-10071-9

14. Fan Z, Chen L, Li J, Tian C, Yajun Z, Huang S, Liu Z, Cheng J. Clinical Features of COVID-19. Related liver functional abnormality. Clinical Gastroenterol and Hepatol. 2020 [acceso: 10/10/2021]; 18(7):1561–6. Disponible en: https://www.cghjournal.org/article/S1542-3565(20)30482-1/fulltext

15. Serin I, Didem N, Hilmi M, Damla S, Babur G, Ulusoy A, et al. A new parameter in COVID-19 pandemic: initial lactate dehydrogenase (LDH)/Lymphocyte ratio for diagnosis and mortality. Journal of Infection and Public Health. 2020 [access: 08/10/2021]; 13(11):1664–70. Disponible en: https://doi.org/10.1016/j.jiph.2020.09.009

16. Lambis L, Belisario Solana JB, Gastelbondo B, Romero D, Garrido D, Puello W, et al. Factores de riesgo asociados a hígado graso de origen no alcohólico en una población del Caribe Colombiano. Rev Col Gastroenterol. 2016 [acceso: 08/10/2021]; 31(2):89-95. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-99572016000200001&lng=en

17. Zinellu A, Arru F, De Vito A., Sassu A, Valdés G, et al. The De Ritis ratio as prognostic biomarker of in-hospital mortality in COVID-19 patients. 2020 [acceso: 11/10/2021]; 51(1):e13427. Disponible en: https://doi.org/10.1111/eci.13427

Downloads

Published

2022-09-15

How to Cite

1.
Vera NS, Saavedra Hernández D, Hidalgo Mesa CJ, Aguila López M, Negrín Medina Y, Rodríguez García I. Liver enzymes in high-risk patients diagnosed with COVID-19. Rev Cubana Med Milit [Internet]. 2022 Sep. 15 [cited 2025 Mar. 14];51(3):e02201994. Available from: https://revmedmilitar.sld.cu/index.php/mil/article/view/1994

Issue

Vol. 51 No. 3 (2022): July - September

Section

Research Article

License

Authors who have publications with this Journal accept the following terms:

  • The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
  • The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
  • Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.